A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring

• Status: Completed
• Trial end date: 2003-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propiverine with respect to micturition chart variables and safety profile.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Propiverine; Tolterodine Tartrate

Criteria

Inclusion Criteria:

• Symptoms of urinary urgency

• Symptoms of urinary frequency (greater than or equal to 8 micturitions per 24 hours) as verified on the patient's micturition chart

• Symptoms of overactive bladder for greater than or equal to 6 months

Exclusion Criteria:

• Stress incontinence as determined by the investigator and confirmed for female patients by a cough provocation test

• An average volume voided of >200 ml per micturition as verified on the micturition chart before randomization

• Total daily urine volume of >3000 ml as verified on the micturition chart before randomization